GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer [Yahoo! Finance]
Forte Biosciences, Inc. (FBRX)
Company Research
Source: Yahoo! Finance
SAN MARINO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient's immune system against the entire repertoire of their own tumor antigens, today announces the appointment of Dr. Noriyuki “Nori” Kasahara as Chief Scientific Officer (CSO). “With more than three decades of distinguished leadership in cancer research and vector technology, Nori brings a wealth of scientific and developmental expertise to GenVivo's leadership team,” said Robert Johnson, M.D., Ph.D., Chief Operating Officer at GenVivo. “His strategic insights will be invaluable as we advance our i n vivo CAR-T and IL-12 vectors into the clinic and validate the GEN2 mechanism of action in our Phase 1/2 clinical trial.” Dr. Kasahara has authored more than 150 peer-reviewed articles in the fields of gene therapy and genetic engineering. His pioneering work includes the developmen
Show less
Read more
Impact Snapshot
Event Time:
FBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBRX alerts
High impacting Forte Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
FBRX
News
- Forte Biosciences (NASDAQ:FBRX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Forte Biosciences (NASDAQ:FBRX) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Forte Biosciences (NASDAQ:FBRX) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness Wire
- Forte Biosciences (NASDAQ:FBRX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
FBRX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 10-Q
- FBRX's page on the SEC website